RT info:eu-repo/semantics/article
T1 Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia
A1 González López, Tomás José
A1 Sánchez González, Blanca
A1 Jarque, Isidro
A1 Bernat, Silvia
A1 Fernández Fuertes, Fernando
A1 Caparrós, Isabel
A1 Soto, Inmaculada
A1 Fernández Rodríguez, Angeles
A1 Bolaños, Estefanía
A1 Pérez Rus, Gloria
A1 Pascual, Cristina
A1 Hernández Rivas, José Angel
A1 López Ansoar, Elsa
A1 Gómez Nuñez, Marta
A1 Martínez Robles, Violeta
A1 Olivera, Pavel
A1 Yera Cobo, Maria
A1 Peñarrubia, María Jesús
A1 Fernández Miñano, Carmen
A1 Cabo, Erik
A1 Martínez Badas, María Paz
A1 Perdomo Hernández, Germán M.
A1 García Frade, Luis Javier
K1 Elderly
K1 Eltrombopag
K1 Immune thrombocytopenia
K1 Primary
K1 Secondary
K1 Aparato circulatorio-Enfermedades
K1 Cardiovascular system-Diseases
AB BackgroundEltrombopag is useful for immune thrombocytopenia (ITP). However, results of clinical trials may not accurately mirror clinical practice reality. Here we evaluated eltrombopag for primary and secondary ITP in our ≥65‐year‐old population.MethodsA total of 106 primary ITP patients (16 with newly diagnosed ITP, 16 with persistent ITP, and 74 with chronic ITP) and 39 secondary ITP patients (20 with ITP secondary to immune disorders, 7 with ITP secondary to infectious diseases, and 12 with ITP secondary to lymphoproliferative disorders [LPD]) were retrospectively evaluated.ResultsMedian age of our cohort was 76 (interquartile range, IQR, 70‐81) years. 75.9% of patients yielded a platelet response including 66.2% complete responders. Median time to platelet response was 14 (IQR, 8‐21) days. Median time on response was 320 (IQR, 147‐526) days. Sixty‐three adverse events (AEs), mainly grade 1‐2, occurred. The most common were hepatobiliary laboratory abnormalities (HBLAs) and headaches. One transient ischemic attack in a newly diagnosed ITP and two self‐limited pulmonary embolisms in secondary ITP were the only thrombotic events observed.ConclusionEltrombopag showed efficacy and safety in ITP patients aged ≥65 years with primary and secondary ITP. However, efficacy results in LPD‐ITP were poor. A relatively high number of deaths were observed.
PB John Wiley & Sons
SN 0902-4441
YR 2020
FD 2020-03
LK http://hdl.handle.net/10259/5243
UL http://hdl.handle.net/10259/5243
LA eng
DS Repositorio Institucional de la Universidad de Burgos
RD 23-nov-2024